《2023年国际多学科专家共识： 代谢相关脂肪性肝病和心血管疾病风险》摘译

周晓东; 田娜; 郑明华

doi:10.3969/j.issn.1001-5256.2023.10.010

《2023年国际多学科专家共识：代谢相关脂肪性肝病和心血管疾病风险》摘译

DOI: 10.3969/j.issn.1001-5256.2023.10.010

周晓东^1a,
田娜^1b,
郑明华^{1b, 2, 3, , ,}

1a.
温州医科大学附属第一医院心脏中心，心血管内科，浙江温州 325000
1b.
温州医科大学附属第一医院心脏中心感染内科，浙江温州 325000
2.
温州医科大学肝病研究所，浙江温州 325000
3.
浙江省慢性肝病重症化精准诊治与转化重点实验室，浙江温州 325000

基金项目:

国家自然科学基金项目 (82070588);

浙江省卫生厅高层次创新人才项目 (2032102600032)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：周晓东，田娜负责文章翻译；郑明华负责文章审校。

详细信息

通信作者:
郑明华， zhengmh@wmu.edu.cn （ORCID： 0000－0003－4984－2631）

计量
- 文章访问数: 2079
- HTML全文浏览量: 249
- PDF下载量: 336
- 被引次数: 0
出版历程
- 收稿日期: 2023-08-07
- 出版日期: 2023-10-30

Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD （2023）

Xiaodong ZHOU^1a,
Na TIAN^1b,
Minghua ZHENG^{1b, 2, 3
, ,
,}

1a.
Department of Cardiovascular Medicine，The Heart Center，The First Affiliated Hospital of Wenzhou Medical University，Wenzhou，Zhejiang 325000，China
1b.
Department of Infectious Diseases，The First Affiliated Hospital of Wenzhou Medical University，Wenzhou，Zhejiang 325000，China
2.
Institute of Hepatology，Wenzhou Medical University，Wenzhou，Zhejiang 325000，China
3.
Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province，Wenzhou，Zhejiang 325000，China

Research funding:

National Natural Science Foundation of China (82070588);

High Level Creative Talents from the Department of Public Health in Zhejiang Province (2032102600032)

More Information

Corresponding author: ZHENG Minghua， zhengmh@wmu.edu.cn （ORCID： 0000－0003－4984－2631）

摘要

摘要: 代谢相关脂肪性肝病（MAFLD）是全球范围内常见的慢性肝病，影响全球超过四分之一的成年人口。MAFLD特征是肝脏脂肪变性和代谢紊乱共存。作为一种代谢功能障碍性疾病，MAFLD与心血管疾病（CVD）有着相似的发病机制。这两种疾病都与肥胖、2型糖尿病和致动脉粥样硬化性血脂异常等公认的心血管危险因素密切相关。越来越多的证据支持MAFLD与CVD之间存在密切联系。然而，作为一种新兴的CVD危险因素，MAFLD与传统的CVD危险因素不同，仍待进一步研究。在这一背景下，本共识使用德尔菲法则，通过两轮调查就MAFLD和CVD风险之间的联系达成一致意见，并探讨了MAFLD与CVD流行病学及临床特征的相关性，以及病理生理机制、监测和管理等一系列问题。‍
- 代谢相关脂肪性肝病 /
- 非酒精性脂肪性肝病 /
- 心血管疾病 /
- 共识
Abstract: Metabolic associated fatty liver disease （MAFLD） is a common chronic liver disease around the world， affecting more than a quarter of the adult population worldwide. MAFLD is characterized by the co-occurrence of hepatic steatosis and metabolic disturbance. As a metabolic disorder， MAFLD shares a similar pathogenesis with cardiovascular disease （CVD）， and both diseases are closely associated with the well-established cardiovascular risk factors such as obesity， type 2 diabetes， and atherogenic dyslipidemia. An increasing amount of evidence has shown that MAFLD is closely associated with CVD； however， as a new risk factor for CVD， MAFLD differs from traditional risk factors for CVD， which requires further investigation. In this context， this consensus statement used the Delphi method to achieve a consensus on the association between MAFLD and the risk of CVD through two rounds of surveys and discussed the association between MAFLD and CVD in terms of epidemiological and clinical characteristics， as well as a range of topics including pathophysiological mechanisms， surveillance， and management.
- Metabolic （dysfunction）－Associated Fatty Liver Disease /
- Non－Alcoholic Fatty Liver Disease /
- Cardiovascular Diseases /
- Consensus

HTML全文

参考文献(1)

[1]	ZHOU XD, TARGHER G, BYRNE CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD[J]. Hepatol Int, 2023, 17( 4): 773－ 791. DOI: 10.1007/s12072－023－10543－8.